➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Mallinckrodt
AstraZeneca
Harvard Business School
McKinsey

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Azacytidine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Azacytidine?

Azacytidine is an investigational drug.

There have been 145 clinical trials for Azacytidine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.

There are two US patents protecting this investigational drug and thirty-two international patents.

Recent Clinical Trials for Azacytidine
TitleSponsorPhase
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaNational Cancer Institute (NCI)Phase 1/Phase 2
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 1/Phase 2
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLNational Cancer Institute (NCI)Phase 1/Phase 2

See all Azacytidine clinical trials

Clinical Trial Summary for Azacytidine

Top disease conditions for Azacytidine
Top clinical trial sponsors for Azacytidine

See all Azacytidine clinical trials

US Patents for Azacytidine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Azacytidine   Start Trial Peptides and combination of peptides for use in immunotherapy against various tumors IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE)   Start Trial
Azacytidine   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Azacytidine   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
Azacytidine   Start Trial Constructs containing multiple expression cassettes for cancer therapy Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Jerusalem, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Azacytidine

Drugname Country Document Number Estimated Expiration Related US Patent
Azacytidine Argentina 104113 2035-03-27   Start Trial
Azacytidine Argentina 112781 2035-03-27   Start Trial
Azacytidine Australia 2016239920 2035-03-27   Start Trial
Azacytidine Australia 2018232952 2035-03-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Mallinckrodt
AstraZeneca
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.